LEIDOS FUNDING TO25, OPTION 2 OBSERVATIONAL STUDY

Leidos 资助 TO25，选项 2 观察性研究

• 批准号: 10935428
• 负责人: ETHAN DMITROVSKY
• 金额: $ 1308.83万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-28 至 2028-08-17
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935428
• 关键词: Biology; Cause of Death; Cessation of life; Childhood; Communicable Diseases; Coronavirus; Data; Disease; Disease Progression; Emerging Communicable Diseases; Enrollment; Funding; Human; Incidence; Infectious Agent; Medical; Medical Research; Observational Study; Pathogenesis; Patient-Focused Outcomes; Protocols documentation; Publishing; Risk Factors; Therapeutic; acute infection; clinical investigation; follow-up; improved; innovation; pathogen; post-COVID-19; previous outbreak; respiratory virus; virology

Infectious diseases remain one of the leading causes of death worldwide despite innovations in medical research and the availability of new treatments. Emerging diseases include outbreaks of previously unknown diseases or known diseases where the incidence in humans has significantly increased in the past two decades. Detailed studies on emerging and re-emerging infectious agents to better understand pathogens’ biology and host pathogenesis are mostly lacking. The initial study protocol under this Task Order is to prepare for a rapid coordinated clinical investigation of acute infections of emerging and re-emerging infectious agents.

传染病仍然是全球医学研究和新疗法可用性的全球死亡目的地创新的主要原因之一。新兴疾病包括爆发以前未知的疾病或已知疾病，在过去的二十年中，人类事件已显着增加。关于新兴和重新出现的传染剂，以更好地了解病原体的生物学和宿主发病机理的详细研究大多缺乏。该任务顺序下的最初研究方案是为对新兴和重新出现感染剂的急性感染进行快速协调的临床研究做准备。